Research
Hormonal
GLP-1-based therapies elicit a clinically significant reduction in body weight.
Practitioners can expect GLP-1 therapies to aid in weight loss for patients with type 2 diabetes or obesity.
StrongSupportsmedium confidence
Glucagon-like peptide-1 (GLP-1)-based therapies elicit a clinically significant reduction in body weight.
Why this rating
The claim is based on human studies, indicating strong evidence.
Source
GLP-1-derived therapies and risk of sarcopenia: myth or reality?
André J. Scheen · Expert Opinion on Drug Safety · 2026
reviewCited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →